24/7 Market News Snapshot 16 January, 2025 – Predictive Oncology Inc. Common Stock (NASDAQ:POAI)

January 16, 2025

DENVER, Colo., 16 January, 2025 (247marketnews.com) – (NASDAQ:POAI) are discussed in this article.
Predictive Oncology Inc. (NASDAQ:POAI) has demonstrated notable momentum in the market, with shares rising to $1.285, a 7.98% increase from the prior close of $1.19. With trading volume reaching 964.13K, the heightened investor interest underscores expectations for sustained price movements. Analysts have identified resistance at $1.30 and support near the opening price of $1.20, indicating potential for further gains should this trend continue.

In parallel, Predictive Oncology has announced a strategic expansion of its pioneering ChemoFx® drug response assay into European markets, while reinforcing its operations in the United States. The assay, which guides treatment selection for ovarian and gynecological cancers, is set to enhance its capabilities to accommodate additional tumor types in the future. This initiative comes as approximately 250,000 gynecologic cancer cases are diagnosed annually across Europe, alongside 115,000 in the United States, highlighting the urgent demand for personalized treatment solutions.

The ChemoFx® assay assesses the in vitro response of a patient’s tumor to various chemotherapeutic agents, equipping healthcare providers with essential insights to tailor treatments effectively. Dr. Arlette Uihlein, Senior Vice President of Translational Medicine, noted that the platform not only develops predictive models to improve drug discovery but also facilitates clinical trial design and biomarker development, reducing associated risks.

With a biobank of approximately 150,000 live cell tumor samples, including a substantial proportion from gynecological cancers, the company’s commitment to personalized oncology is evident. CEO Raymond Vennare emphasized the assay’s value, having been validated against 175 FDA-approved drugs, thereby fortifying its position in enhancing cancer treatment efficacy and survival outcomes. The broadened availability of ChemoFx® promises to drive future growth and benefits for cancer patients, stakeholders, and the broader healthcare landscape.

Related news for (POAI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.